Kimberly-Clark is laying down $40 billion to buy Kenvue in a massive deal that has puzzled some investors as the Tylenol ...
Kimberly-Clark agreed to buy Kenvue in a cash-and-stock transaction that values the Tylenol maker at an enterprise value of about $48.7 billion, including debt.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback